Advertisement
"We are pleased to have licensed the Canadian rights for SANCTURA XR toAllergan," stated Glenn L. Cooper, M.D., chairman and chief executive officerof Indevus. "This agreement further consolidates the rights for SANCTURA XRwithin one highly competent organization. We continue to pursue opportunitiesto obtain marketing partners in Japan, Korea and China, where we agreed tojointly license rights with Rottapharm Madaus."
Advertisement
SANCTURA XR is indicated for the once-daily treatment of overactivebladder (OAB) with symptoms of urge urinary incontinence, urgency and urinaryfrequency. SANCTURA XR was approved by the U.S. Food and Drug Administration(FDA) in August 2007, but has not yet been approved in Canada. In October2007, Allergan, Inc. obtained the U.S. rights to SANCTURA(R) and SANCTURA XRthrough its acquisition of Esprit Pharmaceuticals and began selling SANCTURAXR in the U.S. in January 2008. Indevus previously licensed rights toSANCTURA XR throughout the rest of the world to Rottapharm Madaus , except forCanada, Japan, Korea and China, where Indevus and Rottapharm Madaus agreed tojointly license rights to SANCTURA XR to third party partners.
SANCTURA (trospium chloride 20 mg tablets) was originally developed byRottapharm Madaus and is currently marketed by Rottapharm Madaus and severalRottapharm Madaus licensees as a prescription drug product in Europe and otherterritories, with different trade marks, where it is one of the leadingproducts for OAB / urinary incontinence. Indevus licensed exclusive U.S.rights to SANCTURA(R) from Rottapharm Madaus in late 1999.
About SANCTURA XR(TM)
SANCTURA XR belongs to a class of anticholinergic compounds known asmuscarinic receptor antagonists. These compounds relax detrusor smooth muscletissue found in the bladder, thus decreasing bladder contractions. Overactiveor unstable detrusor muscle function is believed to be the cause of overactivebladder.
SANCTURA XR possesses a quaternary ammonium structure that may beinstrumental in the low incidence of CNS side-effects. At therapeuticconcentrations in vitro, SANCTURA XR does not interact with drugs metabolizedby the Cytochrome P-450 system, a metabolic pathway commonly associated withdrug-drug interactions, and the majority of the absorbed dose is excretedlargely unchanged into the urine.
Patients who have urinary retention, gastric retention, uncontrollednarrow-angle glaucoma or hypersensitivity to SANCTURA XR should not useSANCTURA XR.
About Indevus
Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical companyengaged in the acquisition, development and commercialization of products totreat conditions in urology and endocrinology. The Company's approved productsinclude SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, VANTAS(R)for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty,and DELATESTRYL(R) to treat male hypogonadism. The Indevus developmentpipeline contains multiple compounds within the Compan
